Neurelis, Inc. Report issue

For profit Phase 2 Phase 3
Founded: Encinatas CA United States (2007)

Organization Overview

First Clinical Trial
2011
NCT01364558
First Marketed Drug
2020
diazepam (valium)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NEURALIS s.a. | Neurelis, Inc. | NEURELIS INC

Active Ingredients

Marketed Drugs (1)

diazepam (valium) (2020)

Drugs in Phase 3 Trials (1)

diazepam (valium) (4 trials)

Drugs in Phase 2 Trials (1)

estetrol (NEXTSTELLIS) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epilepsy (Phase 3)

Seizures (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 2